Prakt. lékáren. 2010; 6(6): 271-274

Victoza (liraglutid)

MUDr.Jitka Jurková

Diabetologická ambulance, Městská nemocnice Ostrava

The article informs about Victoza (liraglutid) which is a glucagon-like-peptid-1 analogue (GLP1). It is used to treat patients with diabetes

mellitus type 2 with insufficient compensation of diabetes during metformin and/or derivates of sulfonylurey or metformin and thiazolidindion

therapy. Liraglutid stimulates the insulin secretion depending upon the concentration of glucose in blood and reduces

an incorrectly high secretion of glucagon. Liraglutid also reduces body weight and the amount of body fat thanks to the suppression

of the feeling of hunger and reduction of energy intake. The treatment with Victoza leads to a significant improvement in the level of

glycated hemoglobin, the level of glycaemia on an empty stomach and also in a postprandial way. In clinical studies, the improvement

in the function of beta cells of the pancreas, permanent reduction of body weight, and lower blood pressure were noticeable. Victoza is

applied only in a subcutaneous way. It can be administered at any time of the day, independent of meals. The most frequent side-affects

are gastrointestinal disorders. The side affects disappear after several weeks of treatment. There is a contraindication of Liraglutid in the

diabetes mellitus type 1 therapy and the treatment of diabetic ketoacidosis. Victoza should not be administered during pregnancy and

when breast-feeding. The medication is distributed in pre-filled pens. The medication is reimbursed by the health insurance company

both on the basic or higher level.

Keywords: incretin effect, incretin mimetic, glucagon-like-peptid 1 analogue, diabetes mellitus type 2

Published: December 30, 2010  Show citation